CRISPR / Cas 9 gene editing technology shows promising anti-VEGF affects in lab models of angiogenesis.
Researchers, led by investigators at the Schepens Eye Research Institute of Massachusetts Eye and Ear, and the Department of Ophthalmology, Harvard Medical School, Boston, have shown that recently developed gene editing technology is capable of depleting VEGF2 expression demonstrating a potential therapeutic approach to retinal angiogenesis. The technology, commonly referred to as CRISPR / Cas […]Read full story
Inhibition of soluble epoxide hydrolase (sEH) may slow progression of diabetic retinopathy
Researchers led by investigators at the Institute for Vascular Signaling, Goethe University, Frankfurt, Germany, have identified an enzyme, “soluble epoxide hydrolase” (sEH), to be involved in the loss of pericyte cells and vascular permeability, characteristic of the pathology of diabetic retinopathy. The expression levels of the enzyme were found to be increased in animal models […]Read full story
Artificial intelligence technology provides potentially promising tool for diabetic retinopathy screening.
Researchers based at the Singapore National Eye Center have reported their findings on a novel “deep learning system” (DLS) – a machine learning technology with potential for screening diabetic retinopathy (DR) and related eye diseases. The research, published in the Journal of the American Medical Association (2017; 318 (22): 2211-2223) indicates that the DLS technology […]Read full story